ArticleMaterials today. Bio2025
An AIE-active type I/II photosensitizer with mitochondria-to-nuclei cascade targeting for highly efficient photodynamic cancer therapy.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mitochondria-Damaging Self-Reporting Probe for Cancer Therapy.Angewandte Chemie (International ed. in English) · 2026Article
- Stimuli-Responsive Aggregation-Induced Emission Materials for Tumor Theranostics: Design Strategies and Biomedical Applications.Small science · 2026Review
- Apigenin based nanoplatform achieves non-small cell lung cancer immunotherapy through glycolysis inhibition and photodynamic co-perturbation of organelles.Journal of nanobiotechnology · 2026Article
- A novel photosensitizer berberine derivative B12 induces apoptosis and suppresses HIF-1α expression in colorectal cancer cells via mitochondria-to-nucleus sequential-targeting.Acta pharmacologica Sinica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
photodynamic therapy (PDT) has emerged as a prominent strategy for the treatment of breast cancer, which is prevalent among women globally. Organelles targeted photosensitizers have brought great promise for enhancing the PDT efficiency. Photosensitizers possessing mitochondria and nuclei dual-targeting, especially those multipled with type I/II reactive oxygen species (ROS) generation and aggregation-induced emission (AIE) characteristics are urgently needed to improve the PDT efficiency. Herein, a new amphiphilic compound, 2-(2-(5-(7-(4-((4-butylphenyl)(4-(7-(5-formylthiophen-2-yl)benzo[c] [1,2,5]thiadiazol-4-yl)phenyl)amino)phenyl)benzo[c][1,2,5]thiadiazol-4-yl)thiophen-2-yl)vinyl)-3-methylbenzo[d]thiazol-3-ium iodide (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.